公开(公告)号：EP3775889A1

公开(公告)日：2021-02-17

申请号：EP19781413.0

申请日：2019-04-03

申请人： Genome and Company

发明人： YOON, Kyoung-Wan ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  HOUH, Youn Kyung ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： G01N33/50 ,  G01N33/68 ,  C12Q1/6886

公开(公告)号：EP3795585A1

公开(公告)日：2021-03-24

申请号：EP19804458.8

申请日：2019-05-15

申请人： Genome and Company

发明人： YOON, Kyoung Wan ,  HOUH, Youn Kyung ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： C07K14/705 ,  C07K16/28 ,  A61P31/00 ,  A61P35/00 ,  A61K38/00

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.

公开(公告)号：EP3737945A1

公开(公告)日：2020-11-18

申请号：EP19738069.4

申请日：2019-01-11

申请人： Genome and Company

发明人： YOON, Kyoung-Wan ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  HOUH, Youn Kyung ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： G01N33/50 ,  C12Q1/6886

公开(公告)号：EP4332116A1

公开(公告)日：2024-03-06

申请号：EP21939415.2

申请日：2021-04-29

申请人： Genome and Company

发明人： JEON, Bu Nam ,  HOUH, Youn Kyung ,  KIM, Yun Yeon ,  CHA, Mi Young

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  G01N33/577 ,  A61K39/00

摘要： The present invention relates to anti-CNTN4 antibodies or antigen-binding fragments thereof, and use thereof for activating T cells that upregulate a cell-mediated immune response, for example, use thereof for the treatment of cancer.

公开(公告)号：EP3805258A1

公开(公告)日：2021-04-14

申请号：EP19812551.0

申请日：2019-05-30

申请人： Genome and Company

发明人： YOON, Kyoung Wan ,  HOUH, Youn Kyung ,  JEON, Bu-Nam ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  LEE, Suro ,  CHUNG, Joo-Yeon ,  JEONG, Areum

IPC分类号： C07K14/705 ,  A61K47/68 ,  A61P27/14 ,  A61P31/00 ,  A61P35/00 ,  A61P37/04 ,  A61P37/06 ,  A61K38/00

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing a CD300E inhibitor as an active ingredient. The CD300E inhibitor according to the present invention can increase the activity of immunocytes so as to be usable as an adjuvant. In addition, the CD300E inhibitor according to the present invention enhances the immunity of an individual, thereby enabling cancer to be effectively prevented or treated.

公开(公告)号：EP3792343A1

公开(公告)日：2021-03-17

申请号：EP19799157.3

申请日：2019-05-08

申请人： Genome and Company

发明人： PARK, Hansoo ,  PARK, Shinyoung ,  LEE, Eun Ju ,  YEON, Jae-Sung ,  JEON, Hye Hee ,  KIM, Wonduck ,  CHUNG, Joo-Yeon ,  JEONG, Areum ,  HOUH, Youn Kyung ,  SOHN, Jinyoung ,  KIM, Yun Yeon ,  KIM, Sang Gyun ,  LEE, Suro

IPC分类号： C12N1/20 ,  A23L33/135 ,  A61K35/747 ,  A61P35/00 ,  A23K10/16 ,  A61K35/745 ,  C12R1/46

摘要： The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits effects of directly inhibiting the proliferation of cancer cells and enhancing immunity, thereby having effects of preventing or treating cancers. In particular, the strain has an excellent anticancer effect by secreting metabolites having an anticancer effect while being established in the gut. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Lactococcus lactis GEN3033 strain of the present invention exhibits a better anticancer effect.